Background Acute coronary syndrome (ACS) is a global leading cause of morbidity, with residual inflammation contributing to recurrent events. Colchicine has been proposed as an adjunct therapy, but its efficacy remains uncertain.Methods We performed a systematic review and meta-analysis. PubMed, Embase and Cochrane databases were searched for randomised controlled trials (RCTs) data comparing colchicine versus… Continue reading #Colchicine in acute #coronary syndromes: a systematic review and meta-analysis of randomised controlled trials
Tag: colchicine
Long-term trials of #colchicine for secondary prevention of #vascular events: a meta-analysis
Background and AimsColchicine has emerged as a safe and inexpensive anti-inflammatory medication to target the residual risk of cardiovascular events in the secondary prevention of coronary artery disease. Two recently published randomized controlled trials (RCTs) investigating colchicine in the post-stroke and post-myocardial infarction (MI) populations warrant a re-evaluation of colchicine. New evidence was synthesized in… Continue reading Long-term trials of #colchicine for secondary prevention of #vascular events: a meta-analysis
Efficacy and Safety of Low-Dose #Colchicine after Myocardial #Infarction
We performed a randomized, double-blind trial involving patients recruited within 30 days after a myocardial infarction. The patients were randomly assigned to receive either low-dose colchicine (0.5 mg once daily) or placebo.. ..The primary end point occurred in 5.5% of the patients in the colchicine group, as compared with 7.1% of those in the placebo… Continue reading Efficacy and Safety of Low-Dose #Colchicine after Myocardial #Infarction
2 Medical News 